Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1Mutations in <i>DNMT3A</i>, <i>U2AF1</i>, and <i>EZH2</i> identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1, Published online: 10 January 2018; doi:10.1038/s41408-017-0040-9Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1

Source: Blood Cancer Journal - January 10, 2018 Category: Hematology Authors: Caner Saygin Cassandra Hirsch Bartlomiej Przychodzen Mikkael A. Sekeres Betty K. Hamilton Matt Kalaycio Hetty E. Carraway Aaron T. Gerds Sudipto Mukherjee Aziz Nazha Ronald Sobecks Christopher Goebel Donna Abounader Jaroslaw P. Maciejewski Anjali S. Advan Source Type: research